CXL Ophthalmics CEO Michael D. Webb to Present at 2023 BIO International Convention
CXL Ophthalmics, Inc., a leading clinical-stage biotechnology company focused on innovative treatment for corneal disease, is happy to announce that its CEO, Michael D. Webb, will be presenting at the highly anticipated 2023 BIO International Convention. The presentation will take place today, June 5, from 1:30 PM to 1:45 PM, in Session Room 104B.
The BIO International Convention is a premier gathering of biotechnology and pharmaceutical leaders from around the world. It offers a platform for industry experts to share insights, discuss groundbreaking advancements, and explore collaborations that drive medical innovation forward.
Mr. Webb will provide an overview of CXL Ophthalmics' groundbreaking EpiSmart system. This cutting-edge drug-device combination, currently entering Phase III clinical trials, aims to revolutionize the treatment of keratoconus and corneal ectasia. The EpiSmart system utilizes a unique approach to collagen cross-linking, employing riboflavin (vitamin B-2) and ultraviolet-A (UV-A) light to strengthen the corneas of keratoconus patients.
The EpiSmart system has unique advantages, including decreased recovery time, reduced pain, and lower risk of infection for patients. By eliminating the need for chemical or physical disruption to the epithelium, EpiSmart presents a groundbreaking approach to cross-linking therapy, offering a safer and more convenient alternative for keratoconus patients.
CXL Ophthalmics invites attendees of the BIO International Convention to join Mr. Webb's presentation in Session Room 104B today at 1:30 PM. Attendees will have the opportunity to learn more about the EpiSmart system's potential to transform the treatment landscape for corneal diseases.
About CXL Ophthalmics
CXLO is developing a minimally-invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally. Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.
For more information, please visit www.cxlophthalmics.com.